Top

Supportive Care in Cancer

Published in:

Open Access 01-12-2019 | Prostate Cancer | Original Article

Cross-sectional study of patient-reported fatigue, physical activity and cardiovascular status in men after robotic-assisted radical prostatectomy

Authors: Ruth E. Ashton, Garry A. Tew, Wendy A. Robson, John M. Saxton, Jonathan J. Aning

Published in: Supportive Care in Cancer | Issue 12/2019

Abstract

Purpose

Patient-reported fatigue after robotic-assisted radical prostatectomy (RARP) has not been characterised to date. Fatigue after other prostate cancer (PCa) treatments is known to impact on patient-reported quality of life. The aim of this study was to characterise fatigue, physical activity levels and cardiovascular status post-RARP.

Methods

Between October 2016 and March 2017, men post-RARP or on androgen deprivation therapy (ADT) were invited into the study. Participants were asked to complete the Brief Fatigue Inventory (BFI) and Stage of Change and Scottish Physical Activity Questionnaires (SPAQ) over a 2-week period. Outcome measures were patient-reported fatigue, physical activity levels and the 10-year risk of cardiovascular disease (Q-Risk). Data were analysed in SPSS.

Results

96/117 (82%) men approached consented to participate; of these, 62/96 (65%) returned complete questionnaire data (RARP n = 42, ADT n = 20). All men reported fatigue with 9/42 (21%) post-RARP reporting clinically significant fatigue. Physical activity did not correlate with fatigue. On average, both groups were overweight (BMI 27.0 ± 3.9 kg/m² and 27.8 ± 12.3 kg/m² for RARP and ADT, respectively) and the post-RARP group had an 18.1% ± 7.4% Q-Risk2 score.

Conclusions

A proportion of men is at increased risk of cardiovascular disease within 10 years post-RARP and have substantial levels of fatigue; therefore, clinicians should consider including these factors when counselling patients about RARP. Additionally, men post-RARP did not meet the recommended guidelines for resistance-based exercise. Future research is needed to establish whether interventions including resistance-based exercise can improve health and fatigue levels in this population.

National Institute for Health and Care Excellence (2014) Prostate cancer: diagnosis and managment. Clinical guideline [CG175]

Khadhouri S, Miller C, Fowler S, Hounsome L, McNeill A, Adshead J, McGrath JS (2018) The British Association of Urological Surgeons (BAUS) radical prostatectomy audit 2014/2015 – an update on current practice and outcomes by centre and surgeon case-volume. BJU Int 121(6):886–892. https://doi.org/10.1111/bju.14156 CrossRefPubMed

Djavan B, Eckersberger E, Finkelstein J, Sadri H, Farr A, Apolikhin O, Lepor H (2010) Oncologic, functional, and cost analysis of open, laparoscopic, and robotic radical prostatectomy. Eur Urol Suppl 9(3):371–378. https://doi.org/10.1016/j.eursup.2010.02.009 CrossRef

Köhler N, Gansera L, Holze S, Friedrich M, Rebmann U, Stolzenburg J-U, Truss MC, Fahlenkamp D, Scholz H-J, Brähler E (2014) Cancer-related fatigue in patients before and after radical prostatectomy. Results of a prospective multi-centre study. Support Care Cancer 22(11):2883–2889. https://doi.org/10.1007/s00520-014-2265-5 CrossRefPubMed

Storey DJ, McLaren DB, Atkinson MA, Butcher I, Liggatt S, O’Dea R, Smyth JF, Sharpe M (2012) Clinically relevant fatigue in recurrence-free prostate cancer survivors. Ann Oncol 23(1):65–72. https://doi.org/10.1093/annonc/mdr034 CrossRefPubMed

Blaney JM, Lowe-Strong A, Rankin-Watt J, Campbell A, Gracey JH (2013) Cancer survivors’ exercise barriers, facilitators and preferences in the context of fatigue, quality of life and physical activity participation: a questionnaire-survey. Psychooncology 22(1):186–194. https://doi.org/10.1002/pon.2072 CrossRefPubMed

Higano CS (2003) Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 61(2 Suppl 1):32–38CrossRefPubMed

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed

MDCalc (2018) Charlson Comorbidity Index (CCI). https://www.mdcalc.com/charlson-comorbidity-index-cci. Accessed 20-6-2018 2018

10.

Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, Brindle P (2008) Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. Bmj 336(7659):1475–1482. https://doi.org/10.1136/bmj.39609.449676.25 CrossRefPubMedPubMedCentral

11.

Coghill N, Garside L, Montgomery AA, Feder G, Horwood J (2018) NHS health checks: a cross- sectional observational study on equity of uptake and outcomes. BMC Health Serv Res 18:238. https://doi.org/10.1186/s12913-018-3027-8 CrossRefPubMedPubMedCentral

12.

National Institute for Health and Care Excellence (2015) Cardiovascular Risk Assessment and Lipid Modification: Quality standard [QS100]. NICE. https://www.nice.org.uk/guidance/qs100/resources

13.

Lowther M, Mutrie N, Loughlan C, McFarlane C (1999) Development of a Scottish physical activity questionnaire: a tool for use in physical activity interventions. Br J Sports Med 33(4):244–249CrossRefPubMedPubMedCentral

14.

Ahlberg K, Ekman T, Gaston-Johansson F, Mock V (2003) Assessment and management of cancer-related fatigue in adults. Lancet 362(9384):640–650. https://doi.org/10.1016/s0140-6736(03)14186-4 CrossRefPubMed

15.

Sternberg CN, Molina A, North S, Mainwaring P, Fizazi K, Hao Y, Rothman M, Gagnon DD, Kheoh T, Haqq CM, Cleeland C, de Bono JS, Scher HI (2013) Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol 24(4):1017–1025. https://doi.org/10.1093/annonc/mds585 CrossRefPubMed

16.

Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85(5):1186–1196CrossRefPubMed

17.

Shafqat A, Einhorn LH, Hanna N, Sledge GW, Hanna A, Juliar BE, Monahan P, Bhatia S (2005) Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment†. Ann Oncol 16(9):1545–1550. https://doi.org/10.1093/annonc/mdi267 CrossRefPubMed

18.

Donovan RJ, Jones S, Holman CDAJ, Corti B (1998) Assessing the reliability of a stage of change scale. Health Educ Res 13(2):285–291. https://doi.org/10.1093/her/13.2.285 CrossRefPubMed

19.

Gilbert SE, Tew GA, Bourke L, Winter EM, Rosario DJ (2013) Assessment of endothelial dysfunction by flow-mediated dilatation in men on long-term androgen deprivation therapy for prostate cancer. Exp Physiol 98(9):1401–1410. https://doi.org/10.1113/expphysiol.2013.073353 CrossRefPubMed

20.

Keating NL (2017) Type of androgen deprivation therapy and risk of cardiovascular disease. Eur Urol 72(6):929–930. https://doi.org/10.1016/j.eururo.2017.08.004 CrossRefPubMed

21.

Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA (2016) Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: an analysis of RTOG 94-08. Eur Urol 69(2):204–210. https://doi.org/10.1016/j.eururo.2015.08.027 CrossRefPubMed

22.

Wallis CJ, Mahar AL, Satkunasivam R, Herschorn S, Kodama RT, Lee Y, Kulkarni GS, Narod SA, Nam RK (2016) Cardiovascular and skeletal-related events following localized prostate cancer treatment: role of surgery, radiotherapy, and androgen deprivation. Urology 97:145–152. https://doi.org/10.1016/j.urology.2016.08.002 CrossRefPubMed

23.

Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367(3):203–213. https://doi.org/10.1056/NEJMoa1113162 CrossRefPubMedPubMedCentral

24.

West J (2015) Does physical inactivity increase personalised cardiovascular risk in males and females aged 40–80 years? 2015 8 (1):21

25.

Sheridan SL, Viera AJ, Krantz MJ, Ice CL, Steinman LE, Peters KE, Kopin LA, Lungelow D (2010) The effect of giving global coronary risk information to adults: a systematic review. Arch Intern Med 170(3):230–239. https://doi.org/10.1001/archinternmed.2009.516 CrossRefPubMed

26.

Casebeer L, Huber C, Bennett N, Shillman R, Abdolrasulnia M, Salinas GD, Zhang S (2009) Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract 10:48. https://doi.org/10.1186/1471-2296-10-48 CrossRefPubMedPubMedCentral

27.

Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N (2000) Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol 11(8):971–975CrossRefPubMed

28.

Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud'Homme DG, Malone SC, Wells GA, Scott CG, Slovinec D'Angelo ME (2009) Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 27(3):344–351. https://doi.org/10.1200/JCO.2007.15.4963 CrossRefPubMed

29.

Taaffe DR, Newton RU, Spry N, Joseph D, Chambers SK, Gardiner RA, Wall BA, Cormie P, Bolam KA, Galvao DA (2017) Effects of different exercise modalities on fatigue in prostate cancer patients undergoing androgen deprivation therapy: a year-long randomised controlled trial. Eur Urol 72(2):293–299. https://doi.org/10.1016/j.eururo.2017.02.019 CrossRefPubMed

30.

Luo H-C, Lei Y, Cheng H-H, Fu Z-C, Liao S-G, Feng J, Yin Q, Chen Q-H, Lin G-S, Zhu J-F, Xu J-F, Wang D (2016) Long-term cancer-related fatigue outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with hormonal therapy. Medicine 95(25):e3948. https://doi.org/10.1097/MD.0000000000003948 CrossRefPubMedPubMedCentral

31.

Berger AM, Mooney K, Alvarez-Perez A, Breitbart WS, Carpenter KM, Cella D, Cleeland C, Dotan E, Eisenberger MA, Escalante CP, Jacobsen PB, Jankowski C, LeBlanc T, Ligibel JA, Loggers ET, Mandrell B, Murphy BA, Palesh O, Pirl WF, Plaxe SC, Riba MB, Rugo HS, Salvador C, Wagner LI, Wagner-Johnston ND, Zachariah FJ, Bergman MA, Smith C (2015) Cancer-related fatigue, version 2.2015. J Natl Compr Cancer Netw 13(8):1012–1039CrossRef

32.

Aning JJ, MacKenzie KR, Fabricius M, McColl E, Johnson MI, Tandogdu Z, Soomro NA, Harding C (2018) Detailed analysis of patient-reported lower urinary tract symptoms and effect on quality of life after robotic radical prostatectomy. Urol Oncol 36(8):364.e315–364.e322. https://doi.org/10.1016/j.urolonc.2018.05.017 CrossRef

33.

Ferguson J, Aning J (2015) Prostate cancer survivorship: a nurse-led service model. Br J Nurs 24(Sup18):S14–S21. https://doi.org/10.12968/bjon.2015.24.Sup18.S14 CrossRefPubMed

34.

Department of Health (2011) Factsheet 4: physical activity guidelines for adults (19–64 years) https://www.gov.uk/government/publications/uk-physical-activity-guidelines

35.

Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D’Angelo MES, Wells GA (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21(9):1653–1659. https://doi.org/10.1200/jco.2003.09.534 CrossRefPubMed

36.

Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvao DA (2013) Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis 16(4):328–335. https://doi.org/10.1038/pcan.2013.22 CrossRefPubMed

37.

Ashton RE, Tew GA, Aning JJ, Gilbert SE, Lewis L, Saxton JM (2018) Effects of short-term, medium-term and long-term resistance exercise training on cardiometabolic health outcomes in adults: systematic review with meta-analysis. Br J Sports Med. https://doi.org/10.1136/bjsports-2017-098970

38.

Owen PJ, Daly RM, Livingston PM, Mundell NL, Dalla Via J, Millar JL, Fraser SF (2017) Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial. Trials 18(1):451. https://doi.org/10.1186/s13063-017-2185-z CrossRefPubMedPubMedCentral

39.

Winters-Stone KM, Dieckmann N, Maddalozzo GF, Bennett JA, Ryan CW, Beer TM (2015) Resistance exercise reduces body fat and insulin during androgen-deprivation therapy for prostate cancer. Oncol Nurs Forum 42(4):348–356. https://doi.org/10.1188/15.onf.348-356 CrossRefPubMed

40.

Galvao DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU (2009) Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 12(2):198–203. https://doi.org/10.1038/pcan.2008.51 CrossRefPubMed

41.

Hasenoehrl T, Keilani M, Sedghi Komanadj T, Mickel M, Margreiter M, Marhold M, Crevenna R (2015) The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review. Support Care Cancer 23(8):2479–2497. https://doi.org/10.1007/s00520-015-2782-x CrossRefPubMed

42.

Sutton E, Hackshaw-McGeagh LE, Aning J, Bahl A, Koupparis A, Persad R, Martin RM, Lane JA (2017) The provision of dietary and physical activity advice for men diagnosed with prostate cancer: a qualitative study of the experiences and views of health care professionals, patients and partners. Cancer Causes Control 28(4):319–329. https://doi.org/10.1007/s10552-017-0861-7 CrossRefPubMedPubMedCentral

43.

Hackshaw-McGeagh LE, Sutton E, Persad R, Aning J, Bahl A, Koupparis A, Millett C, Martin RM, Lane JA (2017) Acceptability of dietary and physical activity lifestyle modification for men following radiotherapy or radical prostatectomy for localised prostate cancer: a qualitative investigation. BMC Urol 17:94. https://doi.org/10.1186/s12894-017-0284-5 CrossRefPubMedPubMedCentral

44.

Er V, Lane JA, Martin RM, Persad R, Chinegwundoh F, Njoku V, Sutton E (2017) Barriers and facilitators to healthy lifestyle and acceptability of a dietary and physical activity intervention among African Caribbean prostate cancer survivors in the UK: a qualitative study. BMJ Open 7(10):e017217. https://doi.org/10.1136/bmjopen-2017-017217 CrossRefPubMedPubMedCentral

45.

Roscoe JA, Kaufman ME, Matteson-Rusby SE, Palesh OG, Ryan JL, Kohli S, Perlis ML, Morrow GR (2007) Cancer-related fatigue and sleep disorders. Oncologist 12(Suppl 1):35–42. https://doi.org/10.1634/theoncologist.12-S1-35 CrossRefPubMed

46.

Cohen J (1977) Statistical power analysis for the behavioral sciences, 1st edn. Academic Press, Cambridge

Title: Cross-sectional study of patient-reported fatigue, physical activity and cardiovascular status in men after robotic-assisted radical prostatectomy
Authors: Ruth E. Ashton
Garry A. Tew
Wendy A. Robson
John M. Saxton
Jonathan J. Aning
Publication date: 01-12-2019
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Prostate Cancer
Prostatectomy
Prostatectomy
Fatigue
Published in: Supportive Care in Cancer / Issue 12/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-04794-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2019

Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: which groups specifically benefit? Secondary analyses of a randomized controlled trial

Mood outcomes of a behavioral treatment for urinary incontinence in prostate cancer survivors

Evaluation of the psychological burden during the early disease trajectory in patients with intracranial tumors by the ultra-brief Patient Health Questionnaire for Depression and Anxiety (PHQ-4)

Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations for cancer prevention is associated with better health–related quality of life among long-term colorectal cancer survivors: results of the PROFILES registry

Reply to: “Informal caregiver quality of life in a palliative oncology population”

Sarcopenia in patients with malignant pleural effusion: impact on symptoms, health status, and response to hospitalization

Keynote webinar | Spotlight on antibody–drug conjugates in cancer